← ANALYST RATINGS · TIPRANKS
Genmab (GMAB): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy1 Hold0 Sell
Ratings of 10 analysts in the last 3 months12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $98.52, the highest $360, the lowest $35.00. The average is +166.3% from the last price of $37.00.
Analyst ratings 19
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $40.00 → $45.00+12.5% | Buy | +21.6% | Reiterated | 08.10.26on TipRanks 22:25 | +2.2%next day +0.9% · 5 days +1.8% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $40.00 → $50.00+25.0% | Buy | +35.1% | Reiterated | 07.10.26on TipRanks 06:25 | −2.8%next day −1.2% · 5 days +1.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $39.00 → $43.00+10.3% | Buy | +16.2% | Reiterated | 06.10.26on TipRanks 18:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $38.00 → $42.00+10.5% | Hold | +13.5% | Downgrade | 06.10.26on TipRanks 18:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $38.00 → $42.00+10.5% | Hold | +13.5% | Reiterated | 06.10.26on TipRanks 18:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $35.00 → $39.00+11.4% | Hold | +5.4% | Reiterated | 06.10.26on TipRanks 18:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $38.00 → $42.00+10.5% | Hold | +13.5% | Reiterated | 06.10.26on TipRanks 18:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $39.00 → $43.00+10.3% | Buy | +16.2% | Reiterated | 06.10.26on TipRanks 18:05 | — | |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $43.00 | Buy | +16.2% | Reiterated | 05.10.26on TipRanks 18:30 | −2.3%next day −2.8% · 5 days −3.1% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | — | Buy | — | Reiterated | 05.10.26on TipRanks 08:45 | +10.1%next day −2.3% · 5 days −3.3% | ↗ |
| Charlie Haywood★★★★★★★★★★#6790 · hits 57% · avg +6.7% | Bank of America Securities | $375 → $427+14.0% | Buy | +1,055.2% | Reiterated | 05.10.26on TipRanks 07:45 | +10.1%next day −2.3% · 5 days −3.3% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $54.00 → $58.00+7.4% | Buy | +56.8% | Reiterated | 05.10.26on TipRanks 07:31 | +10.1%next day −2.3% · 5 days −3.3% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 05.10.26on TipRanks 06:25 | +10.1%next day −2.3% · 5 days −3.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $38.00 → $39.00+2.6% | Buy | +5.4% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $38.00 | Buy | +2.7% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $38.00 | Hold | +2.7% | Downgrade | 05.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $35.00 | Hold | −5.4% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $37.00 → $38.00+2.7% | Hold | +2.7% | Downgrade | 05.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $38.00 → $39.00+2.6% | Buy | +5.4% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $40.00 | Buy | +8.1% | Reiterated | 14.09.26on TipRanks 06:55 | +1.0%next day +5.1% · 5 days +4.3% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | — | Buy | — | Reiterated | 12.08.26on TipRanks 08:45 | +1.6%next day −1.0% · 5 days +9.0% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $33.00 → $35.00+6.1% | Hold | −5.4% | Reiterated | 07.08.26on TipRanks Aug 23 05:40 | +4.1%next day −1.2% · 5 days +1.8% | ↗ |
| Rajan Sharma★★★★★★★★★★#5820 · hits 52% · avg +1.9% | Goldman Sachs | $360 | Buy | +873.3% | Reiterated | 07.08.26on TipRanks Aug 23 05:40 | +4.1%next day −1.2% · 5 days +1.8% | ↗ |
| Charlie Haywood★★★★★★★★★★#6790 · hits 57% · avg +6.7% | Bank of America Securities | — | Buy | — | Reiterated | 07.08.26on TipRanks 15:35 | +4.1%next day −1.2% · 5 days +1.8% | ↗ |
| James Gordon CFA★★★★★★★★★★#4717 · hits 61% · avg +4.7% | Barclays | — | Buy | — | Reiterated | 07.08.26on TipRanks 04:41 | +4.1%next day −1.2% · 5 days +1.8% | ↗ |
| Benjamin Jackson CFA★★★★★★★★★★#4175 · hits 57% · avg +7.0% | Jefferies | — | Buy | — | Reiterated | 07.08.26on TipRanks 04:41 | +4.1%next day −1.2% · 5 days +1.8% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $43.00 | Buy | +16.2% | Assigned | 07.08.26on TipRanks 04:00 | +4.1%next day −1.2% · 5 days +1.8% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $40.00 → $42.00+5.0% | Buy | +13.5% | Reiterated | 06.08.26on TipRanks Aug 7 07:45 | +2.1%next day +4.1% · 5 days +3.9% | ↗ |
| Eva Fortea Verdejo★★★★★★★★★★#231 · hits 80% · avg +54.1% | Wells Fargo | $40.00 | Buy | +8.1% | Assigned | 29.06.26on TipRanks Jun 30 05:10 | −2.0%next day +4.8% · 5 days +11.2% | ↗ |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | $32.00 | Buy | −13.5% | Reiterated | 14.06.26on TipRanks Jun 15 07:50 | −3.8%next day +1.2% · 5 days +8.1% | ↗ |
| Asthika Goonewardene★★★★★★★★★★#5130 · hits 41% · avg +2.0% | Truist Financial | $48.00 | Buy | +29.7% | Reiterated | 25.02.26on TipRanks 08:00 | −1.2%next day +0.4% · 5 days −2.6% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Genmab
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 05.10.26: target $151 at a price of $34.75 (+335.6%); now: $98.52 at $37.00 (+166.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 3 | 3 | 3 | 1 | 2 |
| Buy | 12 | 17 | 17 | 21 | 15 | 15 |
| Hold | 3 | 3 | 4 | 4 | 4 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.36 (from $0.24 to $0.47). Last quarter: $0.49.
Sales
Next quarter’s sales estimate — $1.2B (from $1.1B to $1.3B). Last quarter: $1.2B.
Best top-analyst consensus in the sector · Healthcare
About Genmab
- CEO: Jan van de Winkel
- Employees: 3,119
- Carl Jacobsens Vej 30, Copenhagen, CD, 2500, DK
- www.genmab.com
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical S
Data from the stock’s TipRanks forecast page, read 59 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗